腫瘍抑制剤であるCYLDは,デウビキチネーションによってNF-kappaBのシグナリングを否定的に調節する
Andrew Kovalenko1, Christine Chable-Bessia, Giuseppina Cantarella
1Department of Biological Chemistry, The Weizmann Institute of Science, 76100 Rehovot, Israel.
Nature
|August 15, 2003
まとめ
腫瘍抑制剤であるCYLDは,IKK複合体の成分をデウビキチン化することによって,NF-kappaBシグナル伝達を調節する. CYLDの変異は,この機能を損なっており,デウビキチネーションを家族性シリンドロマトーシスの病理生理学と結びつける.
科学分野:
- 細胞生物学 細胞生物学
- 病気の分子メカニズム
- 腫瘍抑制機能は,腫瘍を抑制する機能です.
背景:
- NF-kappaBの転写因子は,炎症,免疫応答,腫瘍生成を含む重要な細胞プロセスを調節する.
- NF-kappaBの活動は,細胞質阻害剤 (IkappaB) によって厳しく制御され,IkappaBキナーゼ (IKK) 複合体によって調節されます.
- NF-kappaBのシグナル伝達の失調は,がんや炎症性疾患を含む様々な疾患に関与しています.
研究 の 目的:
- NF-kappaBシグナル伝達の調節における腫瘍抑制剤であるCYLDの役割を調査する.
- CYLDがIKK複合体と相互作用し,それを調節する分子メカニズムを解明する.
- CYLDの酵素活性とヒトの病理生理学,特に家族性シリンドロマトーシスにおけるその役割との関係を確立する.
主な方法:
- CYLD,NEMO,およびTRAF2.2間のタンパク質-タンパク質相互作用を研究するための共免疫プレシピテーションアッセイ.
- ポリユビキチン鎖に対するCYLDの酵素活性を特徴付けるために,in vitroデウビキチン化アッセイを行う.
- 家族性シリンドロマトーシスで発見されたCYLD断絶の分析,酵素機能への影響を評価する.
- TRAF媒介によるIKK活性化に対するCYLDの調節の評価.
主要な成果:
- CYLDは,IKK複合体のサブユニットであるNEMOと,キーシグナリングアダプタであるTRAF2と直接相互作用する.
- CYLDは,K48に結合していないポリユビキチン鎖に特異的なデウビキチン化活性を持っています.
- CYLDは,IKK複合体のTRAF媒介による活性化を否定的に調節する.
- 家族性シリンドロマトーシスで見つかったCYLDの断片化された形態は,デウビキチン化活性が低下しています.
結論:
- CYLDは,IKK活性化経路のコンポーネントをデウビキチン化することによって,NF-kappaBシグナル伝達の負の調節器として機能します.
- ユビキチネーションは,CYLDによって調節されるプロセスであるTRAF媒介のIKK活性化において重要な役割を果たします.
- 変異によるCYLDのデウビキチン活性低下は,家族性シリンドロマトーシスの病理生理学と関連しています.
関連する概念動画
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


